141 related articles for article (PubMed ID: 26890451)
21. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
22. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
[TBL] [Abstract][Full Text] [Related]
23. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Casasanta N; Kipnis ST; Linville L; Lipinski S; Knoedler A; Marino A; McHenry A; Biagi T; Stark E; Amdur R; Denduluri N; Rodriguez P; Isaacs C; Kaltman R
Clin Breast Cancer; 2020 Apr; 20(2):125-130. PubMed ID: 31526714
[TBL] [Abstract][Full Text] [Related]
24. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jasem J; Amini A; Rabinovitch R; Borges VF; Elias A; Fisher CM; Kabos P
J Clin Oncol; 2016 Jun; 34(17):1995-2002. PubMed ID: 27001563
[TBL] [Abstract][Full Text] [Related]
25. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
Chun DS; Berse B; Venne VL; DuVall SL; Filipski KK; Kelley MJ; Meyer LJ; Icardi MS; Lynch JA
Fam Cancer; 2017 Jan; 16(1):41-49. PubMed ID: 27589855
[TBL] [Abstract][Full Text] [Related]
26. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
27. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.
Bollet MA; Servant N; Neuvial P; Decraene C; Lebigot I; Meyniel JP; De Rycke Y; Savignoni A; Rigaill G; Hupé P; Fourquet A; Sigal-Zafrani B; Barillot E; Thiery JP
J Natl Cancer Inst; 2008 Jan; 100(1):48-58. PubMed ID: 18159071
[TBL] [Abstract][Full Text] [Related]
28. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.
Rohan TE; Xue X; Lin HM; D'Alfonso TM; Ginter PS; Oktay MH; Robinson BD; Ginsberg M; Gertler FB; Glass AG; Sparano JA; Condeelis JS; Jones JG
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 24895374
[TBL] [Abstract][Full Text] [Related]
29. Predicting OncoDx recurrence scores with immunohistochemical markers.
Bradshaw SH; Pidutti D; Gravel DH; Song X; Marginean EC; Robertson SJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):490-6. PubMed ID: 23455176
[TBL] [Abstract][Full Text] [Related]
30. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
31. Who gets genomic testing for breast cancer recurrence risk?
DeFrank JT; Salz T; Reeder-Hayes K; Brewer NT
Public Health Genomics; 2013; 16(5):215-22. PubMed ID: 23899493
[TBL] [Abstract][Full Text] [Related]
32. Application of National Cancer Institute recommended terminology in breast cytology.
Arul P; Masilamani S
J Cancer Res Ther; 2017; 13(1):91-96. PubMed ID: 28508839
[TBL] [Abstract][Full Text] [Related]
33. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
34. What factors influence minority use of National Cancer Institute-designated cancer centers?
Huang LC; Ma Y; Ngo JV; Rhoads KF
Cancer; 2014 Feb; 120(3):399-407. PubMed ID: 24452674
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
[TBL] [Abstract][Full Text] [Related]
36. Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.
Ashraf AB; Daye D; Gavenonis S; Mies C; Feldman M; Rosen M; Kontos D
Radiology; 2014 Aug; 272(2):374-84. PubMed ID: 24702725
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer multigene testing trends and impact on chemotherapy use.
Ray GT; Mandelblatt J; Habel LA; Ramsey S; Kushi LH; Li Y; Lieu TA
Am J Manag Care; 2016 May; 22(5):e153-60. PubMed ID: 27266581
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
39. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM; Arroyo-Alvarez K
Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
[TBL] [Abstract][Full Text] [Related]
40. The interplay between hospital and surgeon factors and the use of sentinel lymph node biopsy for breast cancer.
Yen TWF; Li J; Sparapani RA; Laud PW; Nattinger AB
Medicine (Baltimore); 2016 Aug; 95(31):e4392. PubMed ID: 27495053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
